Dimensional Fund Advisors
NBSE

Dimensional Fund Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Dimensional Fund Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-69
Closed -$41K – 3313
2016
Q4 		$41K Hold
69
– – ﹤0.01% 3273
2016
Q3 		$78K Hold
69
– – ﹤0.01% 3240
2016
Q2 		$75K Hold
69
– – ﹤0.01% 3246
2016
Q1 		$88K Hold
69
– – ﹤0.01% 3238
2015
Q4 		$169K Buy
+69
New +$106K ﹤0.01% 3231

Other funds holding NBSE

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return

Dimensional Fund Advisors's NBSE Position: Q1 2017 in Review

Dimensional Fund Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2017, closing a stake of 69 shares — an estimated $41K sold.

Dimensional Fund Advisors first reported a position in NBSE in Q4 2015 and held it in 5 quarters. The position peaked at $169K in Q4 2015. 40 funds tracked by Wall St. Rank hold NBSE as of Q1 2017.

  • Dimensional Fund Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • Dimensional Fund Advisors sold 69 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $41K.
  • Dimensional Fund Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2015 and held it in 5 quarters.
  • Dimensional Fund Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $169K in Q4 2015.
  • 40 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2017.

Based on Dimensional Fund Advisors's 13F filing for Q1 2017, filed 12 May 2017.